נוביטרופן 5 מג טבליות
cts chemical industries ltd, israel - oxybutynin hydrochloride - טבליה - oxybutynin hydrochloride 5 mg - oxybutynin - oxybutynin - relief of symptoms associated with voiding in patients with uninhibited neurogenic and reflux neurogenic bladder.
דולוקסטין אס.קיי. 30 מג
k.s.kim international (sk- pharma) ltd., israel - duloxetine as hydrochloride - duloxetine as hydrochloride 30 mg - duloxetine
דולוקסטין אס.קיי. 60 מג
k.s.kim international (sk- pharma) ltd., israel - duloxetine as hydrochloride - duloxetine as hydrochloride 60 mg - duloxetine
פולמוקאר וניל
abbott medical laboratories ltd - acid casein 5.8 g / 100 ml; ascorbic acid 77.4 mg / 100 ml - liquid - fat/carbohydrates/proteins/minerals/vitamins, combinations - theraputic nutrition for people with copd (chronic obstructive pulmonary disease). ahigh calorie low carbohydrate formula specifically dasigned to help reduce carbon dioxide producton.
ראפאסאל 4 חוקן גרם
rafa laboratories ltd - mesalazine - חוקן - mesalazine 4 g / 60 g - mesalazine - mesalazine - treatment and prevention of ulcerative colitis and crohn's disease.
רפאסאל 1 גרם חוקן
rafa laboratories ltd - mesalazine - חוקן - mesalazine 1 g - mesalazine - mesalazine - treatment and prevention of ulcerative colitis and crohn's disease.
ניפדילונג 60
cts chemical industries ltd, israel - nifedipine - טבליות בשחרור ממושך - nifedipine 60 mg - nifedipine - nifedipine - chronic stable angina, hypertension.
ניפדילונג 30
cts chemical industries ltd, israel - nifedipine - טבליות בשחרור ממושך - nifedipine 30 mg - nifedipine - nifedipine - chronic stable angina, hypertension.
פרבליפ 40
unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 40 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and nor
פרבליפ 10
unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet and other nonpharmacological measures alone has been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previous myocardial infarction and normal